SGLT2 Inhibitors as the Backbone of Therapy for Cardiovascular and Renal Protection

被引：0
|
作者：
Gragnano, Felice [1 ,2 ]
Terracciano, Fabrizia [1 ,2 ]
Calabro, Paolo [1 ,2 ]
机构：
[1] Univ Campania Luigi Vanvitelli, Dept Translat Med Sci, Viale Abramo Lincoln 5, IT-81100 Caserta, Italy
[2] AORN St Anna & San Sebastiano, Div Clin Cardiol, F Palasciano, IT-81100 Caserta, Italy
来源：
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH | 2024年 / 17卷 / 01期
关键词：
OUTCOMES;
D O I：
10.1007/s12265-023-10415-4
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：227 / 229
页数：3
相关论文
共 50 条
  • [1] SGLT2 Inhibitors as the Backbone of Therapy for Cardiovascular and Renal Protection
    Felice Gragnano
    Fabrizia Terracciano
    Paolo Calabrò
    [J]. Journal of Cardiovascular Translational Research, 2024, 17 : 227 - 229
  • [2] SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection
    Bell, Robert M.
    Yellon, Derek M.
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (06): : 435 - 437
  • [3] Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors
    Davide Margonato
    Giuseppe Galati
    Simone Mazzetti
    Rosa Cannistraci
    Gianluca Perseghin
    Alberto Margonato
    Andrea Mortara
    [J]. Heart Failure Reviews, 2021, 26 : 337 - 345
  • [4] Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors
    Margonato, Davide
    Galati, Giuseppe
    Mazzetti, Simone
    Cannistraci, Rosa
    Perseghin, Gianluca
    Margonato, Alberto
    Mortara, Andrea
    [J]. HEART FAILURE REVIEWS, 2021, 26 (02) : 337 - 345
  • [5] SGLT2 inhibitors: providing cardiovascular protection in type 2 diabetes?
    Wilding, John
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (05): : 379 - 381
  • [6] Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review
    Rabizadeh, Soghra
    Nakhjavani, Manouchehr
    Esteghamati, Alireza
    [J]. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2019, 17 (02)
  • [7] The effect of SGLT2 inhibitors on cardiovascular events and renal function
    Imprialos, Konstantinos P.
    Stavropoulos, Konstantinos
    Doumas, Michael
    Karagiannis, Asterios
    Athyros, Vasilios G.
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (11) : 1251 - 1261
  • [8] Cardiovascular safety of SGLT2 inhibitors
    Gumprecht, Janusz
    [J]. CLINICAL DIABETOLOGY, 2016, 5 (02): : 62 - 65
  • [9] Cardiovascular benefit of SGLT2 inhibitors
    Mohebi, Reza
    Januzzi, James L.
    [J]. CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2022, 59 (03) : 142 - 155
  • [10] SGLT2 inhibitors in cardiovascular medicine
    Varzideh, Fahimeh
    Kansakar, Urna
    Santulli, Gaetano
    [J]. EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2021, 7 (04) : E67 - E68
12345